Medical News

RSS

Sangamo BioSciences awarded a grant to develop zinc finger nuclease-based stem cell therapy for AIDS

Sangamo BioSciences, Inc. announced today that the California Institute for Regenerative Medicine (CIRM) has granted a $14.5 million Disease Team Research Award to develop an AIDS-related lymphoma therapy based on the application of its zinc finger nuclease (ZFN) gene-editing technology in stem cells.

29 Oct 2009

Bankruptcy Rescue to offer free Chapter 7 bankruptcy filing services for breast cancer victims

Attorney Barton W. Morris, Jr., founder of Bankruptcy Rescue, announced today his team of bankruptcy lawyers will select one local family touched by breast cancer and facing financial crisis, to receive free Chapter 7 bankruptcy filing services from essays submitted online at www.mybankruptcyrescue.com/breastcancer before November 30, 2009.

29 Oct 2009

CHS, BPC and CHEP integrated into one hypertension entity

The Heart and Stroke Foundation of Canada today welcomed the integration of the Canadian Hypertension Society (CHS), Blood Pressure Canada (BPC), and the Canadian Hypertension Education Program (CHEP) into one hypertension entity.

29 Oct 2009

CTE cases are misdiagnosed as Alzheimer's disease, says CSTE researchers

The Center for the Study of Traumatic Encephalopathy (CSTE) at Boston University School of Medicine (BUSM) announced today that a recently deceased member of the NFL Hall of Fame suffered from the degenerative brain disease Chronic Traumatic Encephalopathy (CTE) when he died, becoming the 10th former NFL player diagnosed with the disease.

29 Oct 2009

Drug delivery device companies need to rethink their strategies to remain competitive

With increasing decentralization, new cell, gene and RNAI therapies, and a growing emphasis on patient self-care, many drug delivery device companies will need to rethink their strategies in order to remain competitive.

29 Oct 2009

CIRM awards Salk Institute $10.8M grant to develop stem-cell based therapy for Lou Gehrig's Disease

The Salk Institute has been awarded a $10.8 million grant by the California Institute for Regenerative Medicine (CIRM) for translational research focusing on developing a novel stem-cell based therapy for Amyotrophic Lateral Sclerosis (ALS) - or Lou Gehrig's Disease.

29 Oct 2009

Cardiome Pharmam, Astellas Pharma begin patient enrolment for ACT 5 trial

Cardiome Pharma Corp. and its co-development partner Astellas Pharma US, Inc. ("Astellas") announced today that patient enrolment has begun for the ACT 5 trial, a confirmatory Phase 3 clinical trial of KYNAPID(TM) (vernakalant hydrochloride) Injection, a drug product candidate under development for the rapid conversion of atrial fibrillation to sinus rhythm.

29 Oct 2009

FDA Anesthesiology and Respiratory Therapy Devices Panel recommends approval for Asthmatx' Alair System

Asthmatx Inc., announced today that the Anesthesiology and Respiratory Therapy Devices Panel of the Medical Devices Advisory Committee to the U.S. Food and Drug Administration (FDA) voted to recommend that the Alair® System, a device utilized in bronchial thermoplasty for the treatment of severe persistent asthma in patients 18 years and older, be found approvable with conditions.

29 Oct 2009

Premier healthcare alliance offers new program to help physicians provide quality care

The Premier healthcare alliance is offering a new program to bridge the gap between clinical and business processes by helping hospitals and health systems improve quality and outcomes, control costs and increase profitability.

29 Oct 2009

Repros Therapeutics amends its existing license for Proellex

Repros Therapeutics today announced that the Company has entered into an amendment with the National Institutes of Health (NIH) to its existing exclusive license for Proellex® that revises the existing milestones and dates for performance to provide additional time to lift the current clinical hold on Proellex or select a second generation molecule for further development from the family of anti-progestational agents covered by the license.

29 Oct 2009

Regeneration of central nervous system axons can be achieved: Study

Scientists at the University of California, San Diego School of Medicine report that regeneration of central nervous system axons can be achieved in rats even when treatment delayed is more than a year after the original spinal cord injury.

29 Oct 2009

Praxis Version 5 featuring Datum released

Infor-Med Corporation, makers of Praxis Electronic Medical Records (EMR), announced today the beta release of Praxis Version 5 featuring Datum, a tool that allows physicians to use free text to create, store, and share discrete clinical data.

29 Oct 2009

Antibiotic effects of pumpkin may help fight yeast infections

The skin of that pumpkin you carve into a Jack-o'-Lantern to scare away ghosts and goblins on Halloween contains a substance that could put a scare into microbes that cause millions of cases of yeast infections in adults and infants each year.

29 Oct 2009

AAHP updates about the sale of homeopathic medicines to prevent the flu

Recent news articles regarding the scarcity of the "flu shot" (or influenza inoculations) have been widespread. The shortage of the material, due to manufacturing and regulatory issues, has led to increased interest in homeopathic Influenzinum.

29 Oct 2009

ACC and CAA announce national advertising campaign to halt Medicare regulations

The American College of Cardiology (ACC) and the Cardiology Advocacy Alliance (CAA) today announced a national advertising campaign imploring President Obama to halt Medicare regulations that will restrict patients' access to cardiac care.

29 Oct 2009

NIEHS supports research to study the potential effects of BPA on human health

Researchers studying the health effects of the chemical bisphenol A (BPA) gathered in North Carolina to launch an integrated research initiative to produce data that will allow for a comprehensive assessment of its possible human health effects.

29 Oct 2009

Supportive data from a preclinical study of SCY-635 to be presented

Drug discovery company SCYNEXIS, Inc. today announced that supportive data from a preclinical study of the Company’s lead product candidate for hepatitis C (HCV), SCY-635, will be presented in a poster session at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) being held in Boston, MA, October 30-November 3, 2009.

29 Oct 2009

Routine use of HRT increases longevity in postmenopausal women

Hormone replacement therapy (HRT) to treat menopausal estrogen deficiency has been in widespread use for over 60 years. Several observational studies over the years showed that HRT use by younger postmenopausal women was associated with a significant reduction in total mortality; available evidence supported the routine use of HRT to increase longevity in postmenopausal women.

29 Oct 2009

FDA issues a Complete Response Letter regarding NDA for Intermezzo

Transcept Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter regarding the New Drug Application (NDA) for Intermezzo® (zolpidem tartrate sublingual tablet).

29 Oct 2009

Cempra Pharmaceuticals stages a presentation on CEM-101

Cempra Pharmaceuticals today announced a presentation on its novel fluoroketolide antibiotic, CEM-101, at the Infectious Diseases Society of America, 47th Annual Meeting, October 29 to November 1, 2009, in Philadelphia.

29 Oct 2009